Bernstein Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst William Pickering maintains an Outperform rating on Biomarin Pharmaceutical but lowers the price target from $116 to $90.
September 17, 2024 | 11:54 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bernstein analyst William Pickering maintains an Outperform rating on Biomarin Pharmaceutical but lowers the price target from $116 to $90.
The maintenance of an Outperform rating suggests continued confidence in Biomarin's performance, but the lowered price target indicates a more cautious outlook on its valuation. This mixed signal could lead to short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100